MARKET

SLDB

SLDB

Solid Bioscience
NASDAQ
6.86
+0.34
+5.21%
Closed 19:56 02/09 EST
OPEN
6.57
PREV CLOSE
6.52
HIGH
6.99
LOW
5.71
VOLUME
1.97M
TURNOVER
--
52 WEEK HIGH
7.37
52 WEEK LOW
2.410
MARKET CAP
534.46M
P/E (TTM)
-2.7513
1D
5D
1M
3M
1Y
5Y
1D
Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones
Seeking Alpha · 10h ago
Solid Biosciences Price Target Maintained With a $16.00/Share by Needham
Dow Jones · 16h ago
Needham Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
Benzinga · 16h ago
Solid Biosciences To Dose First Patient In IMPACT DUCHENNE Phase 3 Trial In Q1'26
NASDAQ · 19h ago
Solid Bio aligns with FDA on late-stage trial design for Duchenne drug
Seeking Alpha · 19h ago
Solid Biosciences reaches FDA alignment on IMPACT DUCHENNE study design
TipRanks · 20h ago
Reiterating Buy on Solid Biosciences: Conviction in Next‑Generation DMD Gene Therapy and Favorable Risk‑Reward
TipRanks · 20h ago
Solid Biosciences Announces Positive Regulatory Update From Type C Meeting With FDA Supporting Continued Advancement Of SGT-003 As Potential Treatment For Duchenne Muscular Dystrophy
Benzinga · 20h ago
More
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Webull offers Solid Biosciences Inc stock information, including NASDAQ: SLDB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLDB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLDB stock methods without spending real money on the virtual paper trading platform.